In addition, Rspo1 immunoreactivity was inversely correlated with overall survival and disease-free survival in patients diagnosed with glioma, and it was associated with reduced survival after RT-TMZ therapy, further underscoring the clinical significance of Rspo1 in the pathogenesis, prognosis and treatment of glioma. The gene discussed is RSPO1; the disease is central nervous system cancer.